Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma
NCT05629546Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2024
- Primary completion
- Feb 2029
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of cytokine-induced memory-like natural killer cells in melanoma (3 arms), sponsored by Washington University School of Medicine. Primary endpoint: Incidence and severity of adverse events at 15 months. Started Nov 2024; status: recruiting.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05629546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629546.